Navigation Links
MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
Date:10/2/2008

"Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific potency compared to lysate co-incubation in clinical manufacturing scale"

GAITHERSBURG, Md. and YOKOHAMA, Japan, Oct. 2 /PRNewswire/ -- MaxCyte, Inc. and Medinet Co., Ltd. (TSE: #2370) announce a joint poster presentation at The 10th International Symposium on Dendritic Cells. The meeting is being held October 1-5, 2008 in Kobe, Japan.

The presentation is entitled: "Tumor lysate electroloaded mature human DC exhibit enhanced antigen-specific potency compared to lysate co-incubation in clinical manufacturing scale" and will discuss the findings of a study that combined MaxCyte's platform and Medinet's novel immunocell therapy technologies to produce more potent cancer vaccines. The session is scheduled for Friday October 3rd from 1-2 pm and 6:15-8:00 pm.

The study was performed under an exclusive license, development and supply agreement to use MaxCyte's proprietary cell loading system to support clinical development and commercialization of Medinet's cancer immunotherapy service in Japan. MaxCyte has optimized its technology platform for Medinet's novel cancer immuno-cell therapy service for implementation in a closed system, cGMP manufacturing process at Medinet's cell processing centers.

The presentation will discuss how the electroloading of previously matured DC with whole cell tumor lysates generates a DC vaccine that has up to 20-fold enhanced antigen-specific potency compared to traditional DC vaccines obtained via lysate co-incubation of immature DC, followed by maturation. Direct loading of mature DC also saves significant processing time. Using

MaxCyte's cell-loading technology, this process was successfully scaled up to allow processing of large, clinically relevant volumes of DC (>100 million cells) in a closed system, as a single lot that can be subsequently cryopreserved for multiple dosing. The manufacturing methodology uses MaxCyte's proprietary cell loading platform, a technology that has been described in a Master File with CBER-United States FDA and has been cross-referenced in multiple clinical studies.

About MaxCyte

MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in cell-based therapies. MaxCyte's cell transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases. MaxCyte's licenses its cell modification technology to companies developing cell-based therapies and sells instruments and disposables to leading biopharmaceutical companies for drug discovery. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of Chronic Lymphocytic Leukemia (CLL) and a Phase IIa study using engineered stem cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than a dozen commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER). Building on its core technology and relationships, new opportunities are being pursued in the development of first-in-class targeted therapies for cancer, autoimmune and infectious diseases. MaxCyte intends to develop these programs to the proof-of-concept stage and then enter into codevelopment agreements with biopharmaceutical companies. For more information, visit http://www.maxcyte.com.

About Medinet

Medinet is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, Medinet provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. Medinet has extensive experience in autologous cell processing; with more than 7,500 cancer patients treated in actual clinical practice through more than 60,000 cell therapy manufacturing processes. Medinet continues to invest in R&D to improve cell processing

technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and medical institutions. Medinet went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange.

For more information, visit http://www.medinet-inc.co.jp/english/


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
2. MaxCyte to Present at BIO-Europe Spring 2008 Conference
3. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
4. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
5. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
6. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
7. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
8. ViroPharma to Present at Three October Healthcare Conferences
9. BioCryst to Present at the JMP Healthcare Focus Conference
10. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
11. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):